Illustrative image – not actual.Hospira, the US based drug manufacturer, is expected to buy the injectable pharmaceuticals business of Chennai based Orchid Chemicals & Pharmaceuticals for $400 million (Rs 1,860 crore).
The acquisition is to include Orchid's beta-lactam antibiotics manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities) and pharmaceutical research and development facility at Irungattukottai in Chennai, as well as its generic injectable product portfolio and pipeline.
Morgan Stanley and Citigroup Global Markets India acted as financial advisors of Hospira and Orchid, respectively.
